Tandem Diabetes Care (NASDAQ:TNDM) Stock Bought by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Cisneros bought $1,001–$15,000 of Tandem Diabetes Care (NASDAQ: TNDM) shares on September 29, according to a disclosure filed October 12. He also reported several other purchases and sales, including buys of Benchmark Electronics, Cytokinetics, Ultragenyx, YETI and Alkermes.
• TNDM opened at $16.65, versus a 52-week range of $12.26–$29.65. In its latest quarter, Tandem reported a narrower-than-expected loss of $0.31 per share and 5.8% year-over-year revenue growth to $254.56 million.
• Analyst sentiment is mixed, with MarketBeat reporting an overall “Hold” rating and a consensus price target of $27.08. Institutional ownership has increased, highlighted by First Light Asset Management more than doubling its position during the second quarter.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Tandem Diabetes Care stock on September 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Alkermes NASDAQ: ALKS on 9/29/2026.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $16.65 on Wednesday. Tandem Diabetes Care, Inc. has a one year low of $12.26 and a one year high of $29.65. The company has a quick ratio of 2.65, a current ratio of 3.18 and a debt-to-equity ratio of 4.62. The firm's fifty day moving average is $19.20 and its two-hundred day moving average is $18.01.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical device company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.01. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The business had revenue of $254.56 million during the quarter, compared to analyst estimates of $254.99 million. During the same quarter last year, the business posted ($0.78) EPS. The company's revenue was up 5.8% on a year-over-year basis. As a group, equities analysts forecast that Tandem Diabetes Care, Inc. will post -0.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TNDM shares. Citigroup dropped their target price on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a "neutral" rating for the company in a report on Wednesday, September 30th. Oppenheimer reissued an "outperform" rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Barclays raised shares of Tandem Diabetes Care to a "hold" rating in a research note on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Tandem Diabetes Care in a research report on Tuesday, June 23rd. They set a "hold" rating and a $15.50 price target on the stock. Finally, William Blair initiated coverage on shares of Tandem Diabetes Care in a research note on Friday, August 21st. They set an "outperform" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $27.08.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of institutional investors and hedge funds have recently modified their holdings of TNDM. First Light Asset Management LLC lifted its position in Tandem Diabetes Care by 157.4% in the 2nd quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company's stock valued at $51,058,000 after acquiring an additional 2,068,838 shares in the last quarter. Defilade Capital Management L.P. acquired a new position in shares of Tandem Diabetes Care during the 1st quarter worth approximately $14,606,000. Quantinno Capital Management LP lifted its stake in Tandem Diabetes Care by 123.5% in the first quarter. Quantinno Capital Management LP now owns 653,870 shares of the medical device company's stock valued at $12,535,000 after acquiring an additional 361,361 shares during the last quarter. First Trust Advisors LP acquired a new position in shares of Tandem Diabetes Care during the 1st quarter worth about $6,570,000. Finally, Principal Financial Group Inc. raised its holdings in shares of Tandem Diabetes Care by 2.2% in the 1st quarter. Principal Financial Group Inc. now owns 331,541 shares of the medical device company's stock valued at $6,356,000 after purchasing an additional 7,279 shares during the period.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company's products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy.

Tandem's product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.